Ophør som følge af forskellige former for nyreinsufficiens forekom hos 1, 1% af de valsartan- behandlede patienter, 1, 3% af patienterne behandlet med valsartan+captopril og 0, 8% af de captopril- behandlede patienter.
Discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients, 1.3% in valsartan+captopril patients, and 0.8% of captopril patients.